Antibody–drug conjugates come of age in oncology

C Dumontet, JM Reichert, PD Senter… - Nature Reviews Drug …, 2023 - nature.com
Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

Target antigen attributes and their contributions to clinically approved antibody-drug conjugates (ADCs) in haematopoietic and solid cancers

B Esapa, J Jiang, A Cheung, A Chenoweth… - Cancers, 2023 - mdpi.com
Simple Summary Antibody-Drug Conjugates (ADCs) provide effective anti-cancer
treatments. ADC development requires the identification of appropriate tumour-associated …

A review of protein-and peptide-based chemical conjugates: past, present, and future

E Holz, M Darwish, DB Tesar, W Shatz-Binder - Pharmaceutics, 2023 - mdpi.com
Over the past few decades, the complexity of molecular entities being advanced for
therapeutic purposes has continued to evolve. A main propellent fueling innovation is the …

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience

I Vaxman, J Abeykoon, A Dispenzieri, SK Kumar… - Blood cancer …, 2021 - nature.com
Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets
the B cell maturation antigen (BCMA) on plasma cells and showed promising results in …

Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma

Y Zhang, MZ Qiu, JF Wang, YQ Zhang, A Shen… - Cell Reports …, 2022 - cell.com
ARX788 is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug
conjugate with AS269 as cytotoxic payload. In this phase 1 multicenter dose-expansion …

[HTML][HTML] Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

A Hendershot, M Slabaugh, KM Riaz, KN Moore… - Gynecologic Oncology …, 2023 - Elsevier
Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate (ADC)
targeting folate receptor alpha (FRα) and is indicated for the treatment of adult patients with …

Antibody–drug conjugate revolution in breast cancer: the road ahead

T Grinda, E Rassy, B Pistilli - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement Antibody drug-conjugates (ADCs) have revolutionized the treatment of
many types of cancer, including breast cancer. Recently, two new ADCs have been …

Adverse events of antibody–drug conjugates on the ocular surface in cancer therapy

S Domínguez-Llamas, M Caro-Magdaleno… - Clinical and …, 2023 - Springer
Antibody–drug conjugates consist of a monoclonal antibody attached to a cytotoxic
therapeutic molecule by a connector. This association allows a highly specific therapy …

Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer

RL Porter, UA Matulonis - Expert Review of Anticancer Therapy, 2023 - Taylor & Francis
Introduction Mirvetuximab soravtansine (mirvetuximab) is an antibody drug conjugate (ADC)
comprised of a humanized folate receptor alpha (FRα)-binding monoclonal antibody …

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience

R Iula, D De Novellis, F Trastulli, R Della Pepa… - Frontiers in …, 2022 - frontiersin.org
Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed
multiple myeloma (MM) patients; however, available real-life experiences on efficacy and …